



Final Congress Program

THURSDAY, JUNE 23, 2022

16:00 – 18:00 | Registration at RheinMain CongressCenter (RMCC)

FRIDAY, JUNE 24, 2022

07:30 – 17:00 | Registration at RheinMain CongressCenter (RMCC – South Wing)

FRI | 08:30–10:00 | Opening Ceremony

08:30 | Welcome by the Congress President and Program Overview

Richard P. Baum & Frank Rösch – also in the name of Horacio Amaral and Vasko Kramer

08:45 | Greeting Addresses

International Atomic Energy Agency (IAEA)

Diana Paez (Vienna, Austria) – virtual

World Association of Radiopharmaceutical and Molecular Therapy (WARMTH)

Mike Sathekge (Pretoria, South Africa)

Society of Nuclear Medicine and Molecular Imaging (SNMMI)

Richard Wahl (St. Louis, USA)

World Federation of Nuclear Medicine and Biology (WFNMB)

Jean-Luc Urbain (Winston-Salem, USA) – virtual

German Society of Nuclear Medicine (DGN)

Markus Luster (Marburg, Germany)

International Centers for Precision Oncology (ICPO)

Oliver Buck (Munich, Germany)

09:30 – 10:00 | Opening Lecture

Germany as a hub for health innovation

Helge Braun (Berlin, Germany) – virtual



FRI | 10:00 – 12:00 | Session I – Radioisotope Production / Logistics

Chairpersons

Frank Rösch (Mainz, Germany), Horacio Amaral & Vasko Kramer (Santiago, Chile)

Ulli Köster (Grenoble, France) – virtual

NOVEL RADIONUCLIDES FOR THERANOSTICS AND PRISMAP – THE EUROPEAN MEDICAL RADIONUCLIDES PROGRAMME

Jean-Francois Gestin (Nantes, France)

ASTATIN-211 – DEDICATED EUROPEAN NETWORK

Nicholas P. van der Meulen (Villigen, Switzerland)

THE PRODUCTION OF TERBIUM ISOTOPES AND TATTOOS

Andreas Türler (Bern, Switzerland)

PHOTONUCLEAR REACTIONS: THE FUTURE OF LARGE SCALE THERANOSTIC RADIONUCLIDE PRODUCTION

Roy Larsen (Oslo, Norway) – virtual

PB-212 GENERATOR AND RADIUM-224 SUPPLY

Sebastian Marx (Munich, Germany)

LUTETIUM-177: PRODUCTION, SUPPLY AND LOGISTICS – A GLOBAL PERSPECTIVE

Richard Zimmermann (Lalaye, France)

RADIOISOTOPES – INDUSTRIAL PERSPECTIVE FOR THE NEXT TEN YEARS

FRI | 12:00 – 13.15 | LUNCH BREAK. VISIT OF EXHIBITION. E-POSTER VIEWING

FRI | 13:15 – 15:15 | Session II – Radiochemistry, Ligands, Novel Targets and Chelators

Chairpersons

Nicholas P. van der Meulen (Villigen, Switzerland), Patrick Riss (Mainz, Germany), Michael Schultz (Iowa City, USA)

Klaus Kopka (Dresden, Germany)

CAN WE OFFER THE RIGHT BASIC RADIOPHARMACEUTICAL RESEARCH TOOL BOX FOR NEXT GENERATION CLINICAL THERANOSTICS?



Matthias Herth (Copenhagen, Denmark)

PRETARGETED THERANOSTICS – FROM FLUORINE-18 TO ASTATINE-211

Cristina Müller (Villigen, Switzerland)

PRECLINICAL & CLINICAL EVALUATION OF RADIOPHARMACEUTICALS LABELED WITH TERBIUM-161

Xiaoyuan Chen (Singapore) – virtual

EVANS BLUE BASED THERANOSTICS

Vasko Kramer (Santiago de Chile, Chile)

ADOPTION OF ALBUMIN-BINDING LU-177 PSMA LIGANDS – WHAT HAVE WE LEARNED SO FAR?

Lukas Greifenstein (Wiesbaden, Germany)

SQUARIC ACID – A VERSATILE PLATFORM FOR RADIOPHARMACEUTICAL CHEMISTRY

Theodosia Maina-Nock (Athens, Greece)

NEW SSTR2-ANTAGONISTS FOR APPLICATION IN NEUROENDOCRINE TUMOR THERANOSTICS

FRI | 15:15 – 15:45 | COFFEE BREAK. E-POSTER VIEWING. VISIT OF EXHIBITION

FRI | 15:45 – 17:45 | Session III – Neuroendocrine Tumors

Chairpersons

Helmut Mäcke (Freiburg, Germany), Irene Virgolini (Innsbruck, Austria), Giovanni Paganelli (Meldola, Italy)

Lisa Bodei (New York, USA) – virtual

GENOMIC SIGNATURES IN BLOOD FOR PREDICTION OF PRRT EFFICACY AND TOXICITY: AN UPDATE

Andrea Frilling (London, UK)

SURGERY EMBEDDED IN THERANOSTICS - A PROMISING APPROACH FOR TREATMENT OF NEUROENDOCRINE TUMORS

Ebrahim Delpassand (Houston, USA)

PB-212 DOTAMTATE TARGETED ALPHATHERAPY (TAT) IN TREATMENT OF SSTR EXPRESSING NEUROENDOCRINE CANCERS. A BREAKTHROUGH THERAPY.

Michael Schultz (Iowa City, USA)



PB-203 IMAGE-GUIDED RECEPTOR TARGETED PB-212 ALPHA PARTICLE THERAPY FOR CANCER

Michael Müther (Muenster, Germany)

LUCAFAB FOR TREATMENT OF GLIOBLASTOMA

René Leyva Montaña (Havana, Cuba)

NIMOTUZUMAB, A THERANOSTIC MONOCLONAL ANTIBODY FOR RADIONUCLIDE IMAGING AND THERAPY

FRI | 19:00 – 24:00 | FESTIVE EVENING* INCLUDING AWARD CEREMONY

Award Ceremony

- Saul Hertz Young Investigator Award (presented by Barbara Hertz)
- Maurits Geerlings Next Generation Award (presented by Oliver Buck)
- Thomas O'Dorisio Young Investigator Award in NETs (presented by Michael. K. Schultz)

**Must be booked additionally.*



SATURDAY, JUNE 25, 2022

SAT | 07:30 – 13:55 | Presentations by Industry

Timing

Partner

07:30 – 07:55

RPO Clinical

Chair: Rikki N. Waterhouse (Shelbyville, USA)

Coda for a world beyond cancer. For Good

- *Dr. Hugo M. L. Jansen (Ghent, Belgium)*

08:00 – 08:25

ABX-CRO advanced pharmaceutical services

Molecular Radiotherapy - how does it work?

- *Dr. Andreas Kluge, General Manager, ABX-CRO advanced pharmaceutical services GmbH, Dresden/Germany*

08:30 – 08:55

Hermes Medical Solutions

Efficient Quantification of Total Tumor Volume as Predictor of Therapy Outcome in PSMA. An Example of PSMA-Targeted Alpha Therapy in mCRPC Patients.

- *PD Dr. Harun Ilhan, LMU Munich and Die Radiologie, Munich*
- *Dr. Markus Diemling, Hermes Medical Solutions, Stockholm*

09:00 – 09:55

3B Pharmaceuticals GmbH

3BP's innovation alliances – Tailoring compounds to the needs of theranostic radiopharmaceuticals

Chairs: Prof. Wolfgang Weber, TUM and John Carney, iTheranostics

Welcome address

- *Dr. Ulrich Reineke, 3BP*

3BP – innovation for radiopharmaceuticals

- *Dr. Christiane Smerling, 3BP*

Capitalizing on tumour hypoxia: Debio0228, a new radioligand targeting Carbonic Anhydrase 9 (CAIX)

- *Dr. Antoine Attinger, Debiopharm International*

¹⁷⁷Lu-FAP-2286 in patients with advanced or metastatic solid tumors: Initial data from a phase 1/2 clinical trial (LuMIERE)

- *Dr. Lindsey Rolfe, Clovis Oncology*

Closing Remarks

- *Prof. Wolfgang Weber, John Carney*



10:00 – 11:25 MONROL NUCLEAR PRODUCTS CO.

The Current and Future of Lutetium-177 Therapy

Moderator:

- *Ken Herrmann MD MSc, Professor, Department of Nuclear Medicine Essen University*

Speakers

- *Jeremie Calais MD MSc, Associate Professor, Department of Molecular and Medical Pharmacology Director, UCLA Theranostics Program (virtual)*
- *Samer Ezziddin MD Msc, Professor and Director, Department of Nuclear Medicine Saarland University*

Closing Remarks – The World's Lutetium-177 Supplier: Monrol Nuclear Products Co.

11:30 – 12:55 ITM Isotope Technologies Munich SE

ITM Lunch Symposium: Actinium-225 Targeted Radionuclide Therapy – Current Perspective and Future Outlooks

An Evaluation of Current and Prospective ²²⁵Ac Production Methods

- *Neil Quigley, Global Product Manager, ITM Isotope Technologies Munich SE, Garching, Germany*

²²⁵Ac-PSMA for the Treatment of Prostate Cancer - Preclinical Experience

- *Prof. Dr. Katharina Lückerath, Clinic for Nuclear Medicine, University Hospital Essen, Germany*

Current Clinical Experience for ²²⁵Ac-PSMA in mCRPC

- *Prof. Dr. med. Matthias Eiber, Klinik und Poliklinik für Nuklearmedizin, Klinikum rechts der Isar (the University Hospital of the Technical University of Munich), Germany*

13:00 – 13:55 Eckert & Ziegler Strahlen- und Medizintechnik AG

From Brachytherapy to Theranostics and beyond

- *Dr. Harald Hasselmann, Member of the Executive Board, Eckert & Ziegler Strahlen- und Medizintechnik AG*

CXCR4 – paving the way to powerful theranostics in hamatooncological and other indications

- *Dr. Hakim Bouterfa, Managing Director, PentixaPharm GmbH*

SAT | 14:00 – 15:30 | Session IV – Instrumentation, Medical Physics and more

Chairperson

Thomas Beyer (Vienna, Austria), Vikas Prasad (Ulm, Germany), Elcin Zan (New York, USA)

Lorenzo Nardo (Davis, USA)



CLINICAL EXPERIENCE WITH THE EXPLORER TOTAL-BODY PET/CT AFTER MORE THAN 2,000 STUDIES

Ronald Borra (Groningen, The Netherlands) – virtual

FIRST EXPERIENCE WITH LONG AXIAL FIELD OF VIEW PET AT THE UNIVERSITY MEDICAL CENTER GRONINGEN, THE NETHERLANDS

John Prior (Lausanne, Switzerland)

THE 10-PS TIME-OF-FLIGHT PET CHALLENGE: CLINICAL MOTIVATION

Simone Dalm (Rotterdam, The Netherlands)

ONGOING (PRE)CLINICAL DEVELOPMENTS IN NUCLEAR MEDICINE: NOVEL STRATEGIES EXPLORED FOR OPTIMIZING RADIONUCLIDE THERANOSTICS

J. Harvey Turner (Fremantle, Australia)

PRECISION THERANOSTICS: THE PATIENT, MOLECULE AND DOSE

15:30-16:30 | COFFEE BREAK. E-POSTER VIEWING.

SAT | 16:30 – 18:00 | Session V – Dosimetry, Response Evaluation, Artificial Intelligence

Chairpersons

John Babich (Boston, USA), Oyvind Bruland (Oslo, Norway), Johannes Notni (Essen, Germany)

Richard Wahl (St. Louis, USA)

“TO DO OR NOT TO DO”. PRACTICAL CONSIDERATIONS CONCERNING PATIENT-SPECIFIC DOSIMETRY

Wolfgang Weber (Munich, Germany) – virtual

EVALUATION OF THERAPY RESPONSE – OLD AND NEW CONCEPTS

Jeremie Calais (Los Angeles, USA) – virtual

NEW PSMA PET CRITERIA FOR PATIENT SELECTION AND THERAPY RESPONSE ASSESSMENT TO LUPSMA THERAPY

Kuangyu Shi (Bern, Switzerland)

ARTIFICIAL INTELLIGENCE AND COMPUTATIONAL MODELLING FOR PERSONALIZED TREATMENT PLANNING OF RADIONUCLIDE THERAPY

Thomas Beyer (Vienna, Austria)

THE HUMAN CONNECTOME – INTERORGAN IMAGING WITH TB-PET



SUNDAY, JUNE 26, 2022

SUN | 08:00 – 10:00 | Session VI – Prostate Cancer

Chairpersons

Richard P. Baum (Wiesbaden, Germany), Elcin Zan (New York, USA), Juan P. Olivia (Havana, Cuba)

Oliver Sartor (New Orleans, USA)

PIVOTAL PHASE III TRIALS WITH PSMA TARGETED THERAPY: DESIGN CONSIDERATIONS AND DATA ANALYSES

Matthias Eiber (Munich, Germany)

CURRENT STATUS OF PSMA-PET IMAGING

Andrei Iagaru (Stanford, USA)

A DECADE OF GRPR PET IMAGING – WHERE ARE WE AND WHERE ARE WE GOING?

Mike Sathegke (Pretoria, South Africa)

RADIOTHERANOSTICS WITH ²²⁵AC-PSMA

Bernd Krause (Rostock, Germany)

PSMA VS. BOMBESIN

Chandrasekhar Bal (New Delhi, India)

ACTINIUM-225 – THE DRIVING FORCE OF THERANOSTICS

Asta Juzeniene (Oslo, Norway)

DUAL ALPHA TECHNOLOGY

Michael Bachmann (Dresden, Germany)

RADIOIMMUNOTHERANOSTICS

SUN | 10:00 – 10:30 | COFFEE BREAK. E-POSTER VIEWING

SUN | 10:30 – 12:30 | Session VII – Tumor Microenvironment, Novel Targets

Chairperson

Hakim Bouterfa (Würzburg, Germany), Michael C. Kreissl (Magdeburg, Germany), Baljinder Singh (Chandigarh, India)



Andrew Scott (Melbourne, Australia) - virtual

ON THE HISTORY/BEGINNINGS OF FAP

Pieter van der Veken (Antwerp, Belgium)

FAP INHIBITORS AND SUBSTRATES

Martin Pomper (Baltimore, USA) – virtual

FAP RADIOTHERANOSTICS FOR CANCER

Frederik Giesel (Duesseldorf, Germany)

FAP-LIGANDS: IMPACT IN ONCOLOGICAL AND NON-ONCOLOGICAL DISEASES

Frank Rösch (Mainz, Germany)

THERANOSTIC FAP INHIBITORS: FROM MONOMERS FOR DIAGNOSIS TO DIMERS FOR THERAPY?

Jingjing Zhang (Singapore)

PEPTIDE-TARGETED RADIOLIGAND THERAPY (PTRT) USING CANCER-ASSOCIATED FIBROBLASTS AS TARGET IN SOLID TUMORS: FIRST CLINICAL EXPERIENCE WITH LU-177, AC-225 AND Y-90 LABELED PEPTIDES – INCLUDING TANDEM THERAPIES – AGAINST THE FIBROBLAST ACTIVATING PROTEIN

SUN | 12:30 – 13.45 | LUNCH BREAK. VISIT OF EXHIBITION. E-POSTER VIEWING

SUN | 13:45 – 15:45 | Session VIII – Novel Indications/Concepts, Genetics, Radiovaccination, Radioprotectors

Chairpersons

Andrea Frilling (London, UK), Thomas Langbein (Munich, Germany), Susanne Kossatz (Munich, Germany)

Patricia Grabowski (Berlin, Germany) – virtual

GENOMICS AND CANCER

Marianne Pavel (Erlangen, Germany)

NEUROENDOCRINE NEOPLASMS – NOVEL THERAPIES AND COMBINATIONS

Ralph Wirtz (Cologne, Germany)

RADIOVAXX – HOW TO USE THE IMMUNOGENIC EFFECT OF RADIOLIGAND THERAPIES IN LUMINAL VERSUS BASAL TUMORS ACROSS ENTITIES

Andreas Buck (Würzburg, Germany) – virtual

CXCR4 – A VERSATILE TARGET FOR THERANOSTICS OF HEMATOLOGICAL MALIGNANCIES AND SOLID TUMORS



Johannes Notni (Essen, Germany)

THERE IS A WORLD BEYOND AVB3-INTEGRIN: RADIOPHARMACEUTICALS TARGETING DIFFERENT INTEGRIN SUBTYPES

Jens Kaufmann (Berlin, Germany)

THE IMPACT OF SPECIFIC ACTIVITY ON THERANOSTIC PERFORMANCE – THE TOOLBOX OF RADIOMOLECULAR MEDICINE

Jörg Müller (Berlin, Germany)

SAFETY OF HIGH-DOSE BOTULINUM TOXIN INJECTIONS FOR PAROTID AND SUBMANDIBULAR GLAND RADIOPROTECTION

SUN | 15:45 – 16:15 | COFFEE BREAK. E-POSTER VIEWING.

SUN | 16:15 – 18:00 | Session IX – Patient Panel Discussion under the Patronage of ICPO and Oncidium Foundations

PATIENT COMMUNICATION AND EDUCATION: IMPROVING COMMUNICATION FROM PROVIDERS, PROFESSIONAL SOCIETIES AND REGULATORS ENABLING GREATER ACCEPTANCE OF THERANOSTICS IN THE PATIENT COMMUNITY

- Leader: Josh Mailman, President NorCal CarciNETs (Oakland, USA)
- Patients panelists*: F. Acosta (Argentina), A.L. Dellon (USA), M. Enascescu, (Romania), I. Ghazal (Jordan), P. Gruenberg (USA) S. Leyden (Australia), M. McDonnell (Ireland), A. Nilsson (Sweden)
- Physicians panelists* from Nuclear Medicine/Oncology/Neuroendocrinology/Urology: C.S. Bal (India), R.P. Baum (Germany), O. Bruland (Norway), M. Pavel (Germany), V. Prasad (Germany), M. Sathekge (South Africa), O. Sartor (USA) J. S. Singh (USA), J. H. Turner (Australia), J.P. Oliva (Cuba), E. Zan (USA)

**Indicative list pending travel confirmations*

SUN | 18:00 – 18:15 | POSTER PRIZES / CLOSING CEREMONY / FUTURE OUTLOOK

Frank Rösch / Vasko Kramer / Horacio Amaral / Richard P. Baum